For decades, cannabis activists and growers were focused on cultivating high-THC strains of cannabis, and struggled to convince the world of its medicinal benefits. The medical cannabis movement continues to tout the therapeutic properties of THC, but is facing a critical sea change as research continues to reveal the immense health benefits of CBD—without a need for the “high” from THC at all.
In fact, there have been more scientific studies on CBD in the last decade than in the years since its discovery. The results of this research have been so promising for so many ailments that it might be non-psychoactive, non-addictive CBD that finally brings cannabis prohibition to an end. As the push for cannabis legalization continues, the demand for access to CBD for research, clinical trials, and drug development will only increase. Hundreds of scientists from pharmaceutical companies—including GW pharma, Merck, Pfizer, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, and Allergan—are already regularly attending meetings of the International Cannabinoid Research Society. The question is, will the rest of the world be ready?